Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,438 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease.
Suzuki K, Yanagihara T, Matsumoto K, Kusaba H, Yamauchi T, Ikematsu Y, Tanaka K, Otsubo K, Inoue H, Yoneshima Y, Iwama E, Arimura-Omori M, Harada E, Hamada N, Okamoto I, Nakanishi Y. Suzuki K, et al. Among authors: inoue h. Int Immunol. 2020 Jul 28;32(8):547-557. doi: 10.1093/intimm/dxaa022. Int Immunol. 2020. PMID: 32253426
Absence of LTB4/BLT1 axis facilitates generation of mouse GM-CSF-induced long-lasting antitumor immunologic memory by enhancing innate and adaptive immune systems.
Yokota Y, Inoue H, Matsumura Y, Nabeta H, Narusawa M, Watanabe A, Sakamoto C, Hijikata Y, Iga-Murahashi M, Takayama K, Sasaki F, Nakanishi Y, Yokomizo T, Tani K. Yokota Y, et al. Among authors: inoue h. Blood. 2012 Oct 25;120(17):3444-54. doi: 10.1182/blood-2011-10-383240. Epub 2012 Aug 30. Blood. 2012. PMID: 22936657 Free article.
TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
Narusawa M, Inoue H, Sakamoto C, Matsumura Y, Takahashi A, Inoue T, Watanabe A, Miyamoto S, Miura Y, Hijikata Y, Tanaka Y, Inoue M, Takayama K, Okazaki T, Hasegawa M, Nakanishi Y, Tani K. Narusawa M, et al. Among authors: inoue m, inoue h, inoue t. Cancer Immunol Res. 2014 Jun;2(6):568-80. doi: 10.1158/2326-6066.CIR-13-0143. Epub 2014 Apr 10. Cancer Immunol Res. 2014. PMID: 24830413
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.
Murahashi M, Hijikata Y, Yamada K, Tanaka Y, Kishimoto J, Inoue H, Marumoto T, Takahashi A, Okazaki T, Takeda K, Hirakawa M, Fujii H, Okano S, Morita M, Baba E, Mizumoto K, Maehara Y, Tanaka M, Akashi K, Nakanishi Y, Yoshida K, Tsunoda T, Tamura K, Nakamura Y, Tani K. Murahashi M, et al. Among authors: inoue h. Clin Immunol. 2016 May;166-167:48-58. doi: 10.1016/j.clim.2016.03.015. Epub 2016 Apr 9. Clin Immunol. 2016. PMID: 27072896 Clinical Trial.
A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors.
Hijikata Y, Okazaki T, Tanaka Y, Murahashi M, Yamada Y, Yamada K, Takahashi A, Inoue H, Kishimoto J, Nakanishi Y, Oda Y, Nakamura Y, Tani K. Hijikata Y, et al. Among authors: inoue h. PLoS One. 2018 Jan 2;13(1):e0187878. doi: 10.1371/journal.pone.0187878. eCollection 2018. PLoS One. 2018. PMID: 29293510 Free PMC article. Clinical Trial.
6,438 results